FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Thomas Bauknecht

Research Profile

Disorders

Procedures

Chemicals & Drugs

Anatomy

Co-author Network

Publications

TOP 3
Andreas Schneeweiss; F Marmé; Amparo Ruiz; A G Manikhas; A Bottini; M Wolf; Hans-Peter Sinn; Kambiz Mansouri; L Kennedy; Thomas Bauknecht
A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer.
Karen Bräutigam; Dirk Olaf Bauerschlag; Marion Tina Weigel; Julia Biernath-Wüpping; Thomas Bauknecht; Norbert Arnold; Nicolai Maass; Ivo Meinhold-Heerlein
Combination of enzastaurin and pemetrexed inhibits cell growth and induces apoptosis of chemoresistant ovarian cancer cells regulating extracellular signal-regulated kinase 1/2 phosphorylation.
Andreas Schneeweiss; Ilka Lauschner; Amparo Ruiz; Angel Guerrero; Pedro Sánchez-Rovira; Miguel Angel Seguí; Kay Goerke; Michael Wolf; Alexeyg G Manikhas; Juergen Wacker; Frederik Marmé; Peter Lichter; Hans-Peter Sinn; Christof Sohn; Kambiz Mansouri; Thomas Bauknecht; Meinhard Hahn
Doxorubicin/pemetrexed followed by docetaxel versus doxorubicin/ cyclophosphamide followed by docetaxel as neoadjuvant treatment for early-stage breast cancer: a randomized phase II trial.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Thomas Bauknecht (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Andreas Schneeweiss; F Marmé; Amparo Ruiz; A G Manikhas; A Bottini; M Wolf; Hans-Peter Sinn; Kambiz Mansouri; L Kennedy; Thomas Bauknecht
A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(3):609-17.
2009: Karen Bräutigam; Dirk Olaf Bauerschlag; Marion Tina Weigel; Julia Biernath-Wüpping; Thomas Bauknecht; Norbert Arnold; Nicolai Maass; Ivo Meinhold-Heerlein
Combination of enzastaurin and pemetrexed inhibits cell growth and induces apoptosis of chemoresistant ovarian cancer cells regulating extracellular signal-regulated kinase 1/2 phosphorylation.
Translational oncology 2009;2(3):164-73.
2007: Andreas Schneeweiss; Ilka Lauschner; Amparo Ruiz; Angel Guerrero; Pedro Sánchez-Rovira; Miguel Angel Seguí; Kay Goerke; Michael Wolf; Alexeyg G Manikhas; Juergen Wacker; Frederik Marmé; Peter Lichter; Hans-Peter Sinn; Christof Sohn; Kambiz Mansouri; Thomas Bauknecht; Meinhard Hahn
Doxorubicin/pemetrexed followed by docetaxel versus doxorubicin/ cyclophosphamide followed by docetaxel as neoadjuvant treatment for early-stage breast cancer: a randomized phase II trial.
Clinical breast cancer 2007;7(7):555-8.
2007: Ivo Meinhold-Heerlein; Dirk Bauerschlag; Yingyao Zhou; Lisa M Sapinoso; Keith Ching; Henry F Frierson; Karen Bräutigam; Jalid Sehouli; Elmar Stickeler; Dominique Könsgen; Felix Hilpert; Constantin S von Kaisenberg; Jacobus Pfisterer; Thomas Bauknecht; Walter Jonat; Norbert Arnold; Garret M Hampton
An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(2 Pt 1):458-66.
2005: Ivo Meinhold-Heerlein; Dirk Bauerschlag; Felix Hilpert; Petre Dimitrov; Lisa M Sapinoso; Marzenna Orlowska-Volk; Thomas Bauknecht; Tjoung-Won Park; Walter Jonat; Anja Jacobsen; Jalid Sehouli; Jutta Luttges; Maryla Krajewski; Stan Krajewski; John C Reed; Norbert Arnold; Garret M Hampton
Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential.
Oncogene 2005;24(6):1053-65.
2003: Andreas du Bois; Hans-Joachim Lück; Werner Meier; Hans-Peter Adams; Volker Möbus; Serban Costa; Thomas Bauknecht; Barbara Richter; Matthias Warm; Willibald Schröder; Sigrid Olbricht; Ulrike Nitz; Christian Jackisch; Günther Emons; Uwe Wagner; Walther Kuhn; Jacobus Pfisterer
A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.
Journal of the National Cancer Institute 2003;95(17):1320-9.
2003: Thomas Bauknecht; A Hefti; Günther Morack; C Villena-Heinsen; D Wallwiener; Dirk Elling; G V Minckwitz; Kambiz Mansouri; Johannes Blatter; Georg-Peter Breitbach
Gemcitabine combined with cisplatin as first-line treatment in patients 60 years or older with epithelial ovarian cancer: a phase II study.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2003;13(2):130-7.
2002: Andreas M Kaufmann; Peter L Stern; Elaine M Rankin; Harald Sommer; Volkmar Nuessler; Achim Schneider; Malcom Adams; Toli S Onon; Thomas Bauknecht; Uwe Wagner; Karlijn Kroon; Julian Hickling; Christopher M Boswell; Simon N Stacey; Henry C Kitchener; Jennifer Gillard; Jantien Wanders; John St Clair Roberts; Heinz Zwierzina
Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(12):3676-85.
2002: M Hagedorn; B Buxmeyer; Y Schmitt; Thomas Bauknecht
Survey of genital lichen sclerosus in women and men.
Archives of gynecology and obstetrics 2002;266(2):86-91.
2002: Juan José Hernando; Tjoung-Won Park; Kirsten Kübler; Ruth Offergeld; Harald Schlebusch; Thomas Bauknecht
Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial.
Cancer immunology, immunotherapy : CII 2002;51(1):45-52.
2002: Thomas Bauknecht; Ivo Meinhold-Heerlein
Gene therapy of ovarian cancer.
Current women's health reports 2002;2(1):39-46.
2002: Bois A du; Werner Meier; Hans-Joachim Lück; G Emon; V Moebus; Willibald Schroeder; Serban Costa; Thomas Bauknecht; Sigrid Olbricht; Christian Jackisch; Barbara Richter; Uwe Wagner
Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(2):251-7.
2001: Uwe Wagner; Siegmund Köhler; Silke Reinartz; Patrick Giffels; Jens Huober; Kirsten Renke; Harald Schlebusch; H J Biersack; Volker Möbus; Rolf Kreienberg; Thomas Bauknecht; Dieter Krebs; Diethelm Wallwiener
Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin. Cancer Res., 7:1112-1115, 2001.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(5):1154-62.
2001: Ivo Meinhold-Heerlein; Frank Stenner-Liewen; Heike Liewen; Shinichi Kitada; Maryla Krajewska; Stan Krajewski; Juan M Zapata; Anne Monks; Dominic A Scudiero; Thomas Bauknecht; John C Reed
Expression and potential role of Fas-associated phosphatase-1 in ovarian cancer.
The American journal of pathology 2001;158(4):1335-44.
2001: T Brandstetter; Elena Ninci; Hertha Bettendorf; G Perewusnyk; J Stolte; Dieter Herchenbach; D Sellin; E Wagner; OR Köchli; Thomas Bauknecht
Granulocyte colony-stimulating factor (G-CSF) receptor gene expression of ovarian carcinoma does not correlate with G-CSF caused cell proliferation.
Cancer 2001;91(7):1372-83.
2001: Ivo Meinhold-Heerlein; Elena Ninci; Hans Ikenberg; T Brandstetter; Christian Ihling; I Schwenk; Andreas Straub; B Schmitt; Hertha Bettendorf; R Iggo; Thomas Bauknecht
Evaluation of methods to detect p53 mutations in ovarian cancer.
Oncology 2001;60(2):176-88.
2001: Uwe Ulrich; Kerstin Rhiem; Jan Schmolling; Christian Flaskamp; I Paffenholz; H Sälzer; Thomas Bauknecht; Harald Schlebusch
Cross-linked type I collagen C- and N-telopeptides in women with bone metastases from breast cancer.
Archives of gynecology and obstetrics 2001;264(4):186-90.
2000: Andreas du Bois; Hans-Joachim Lück; Jacobus Pfisterer; W Meier; Thomas Bauknecht
[Anthracyclines in therapy of ovarian carcinoma: a systematic review of primary and 2nd-line therapy after platinum].
Zentralblatt für Gynäkologie 2000;122(5):255-67.
1999: Andreas du Bois; M Schlaich; Hans-Joachim Lück; A Mollenkopf; U Wechsel; M Rauchholz; Thomas Bauknecht; Hans-Gerd Meerpohl
Evaluation of neurotoxicity induced by paclitaxel second-line chemotherapy.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1999;7(5):354-61.
1999: Thomas Bauknecht; B Randelzhofer; B Schmitt; Z Ban; Juan José Hernando
Response to IL-6 of HPV-18 cervical carcinoma cell lines.
Virology 1999;258(2):344-54.
1999: Andreas du Bois; Hans-Joachim Lück; Thomas Bauknecht; Werner Meier; Barbara Richter; Walther Kuhn; Jens Quaas; Jacobus Pfisterer
First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: a phase I/II study of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(1):46-51.
1998: Ivo Meinhold-Heerlein; T Brandstetter; Friedrich Kommoss; Hertha Bettendorf; M Hagedorn; Thomas Bauknecht
Localization of cytokeratin 10 mRNA in human epidermis using nonradioactive in situ hybridization as a routine method.
Archives of dermatological research 1998;290(5):286-8.
1998: Klaus Mross; B Hauns; Brigitte Häring; Thomas Bauknecht; Hans-Gerd Meerpohl; Clemens Unger; H Maier-Lenz
Clinical phase I study with one-hour paclitaxel infusion.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(5):569-72.
1998: T Brandstetter; Elena Ninci; U Falken; E Wagner; R Hess; Thomas Bauknecht
rhG-CSF affects genes involved in mitogen signalling and early gene expression in the ovarian cancer cell line HEY.
International journal of cancer. Journal international du cancer 1998;75(6):847-54.
1998: Thomas Bauknecht; Y Shi
Overexpression of C/EBPbeta represses human papillomavirus type 18 upstream regulatory region activity in HeLa cells by interfering with the binding of TATA-binding protein.
Journal of virology 1998;72(3):2113-24.
1998: C Ruf; E Kohlberger; Thomas Bauknecht; Eduard H Farthmann
[Strategy and outcome of interdisciplinary therapy of ovarian carcinomas].
Langenbecks Archiv für Chirurgie. Supplement. Kongressband. Deutsche Gesellschaft für Chirurgie. Kongress 1998;115():1494-6.
1997: H Maier-Lenz; B Hauns; B Haering; J Koetting; Klaus Mross; Clemens Unger; Thomas Bauknecht; Andreas du Bois; Hans-Gerd Meerpohl; N Hollaender; K Diergarten
Phase I study of paclitaxel administered as a 1-hour infusion: toxicity and pharmacokinetics.
Seminars in oncology 1997;24(6 Suppl 19):S19-16-S19-19.
1997: Andreas du Bois; Hans-Joachim Lück; Werner Meier; Volker Möbus; S Costa; Barbara Richter; Matthias Warm; Thomas Bauknecht; W Schröder; Sigrid Olbricht; Ulrike Nitz; Christian Jackisch
Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
Seminars in oncology 1997;24(5 Suppl 15):S15-44-S15-52.
1997: Andreas du Bois; Hans-Joachim Lück; Werner Meier; Volker Möbus; S Costa; Barbara Richter; Thomas Bauknecht; Matthias Warm; W Schroeder; Sigrid Olbricht; Ulrike Nitz; Christian Jackisch
Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
Seminars in oncology 1997;24(4 Suppl 11):S11-28-S11-33.
1997: U Schwarz-Roeger; B Petzoldt; R Waldschmidt; R P Walker; Thomas Bauknecht; Marion Kiechle
UGP--a tumor marker of gynecologic and breast malignancies? Specificity and sensitivity in pretherapeutic patients and the influence of hormonal substitution on the expression of UGP.
Anticancer research 1997;17(4B):3041-5.
1997: Andreas du Bois; Hans-Joachim Lück; Thomas Bauknecht; Volker Möbus; H Bochtler; K Diergarten; Hans-Gerd Meerpohl
Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(4):355-61.
1997: Hans-Gerd Meerpohl; Andreas du Bois; H J Luck; H Kühnle; Volker Möbus; R Kreienberg; Thomas Bauknecht; OR Köchli; H Bochtler; K Diergarten
Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer: a phase I trial.
Seminars in oncology 1997;24(1 Suppl 2):S2-17-S2-22.
1996: C A Schäfer; Andreas du Bois; W Vach; Heinrich Prömpeler; Thomas Bauknecht; M Breckwoldt
[Changes in serotonin metabolism in pre-eclampsia].
Geburtshilfe und Frauenheilkunde 1996;56(8):418-22.
1996: Norbert Arnold; L Hagele; L Walz; Werner Schempp; Jacobus Pfisterer; Thomas Bauknecht; Marion Kiechle
Overrepresentation of 3q and 8q material and loss of 18q material are recurrent findings in advanced human ovarian cancer.
Genes, chromosomes & cancer 1996;16(1):46-54.
1996: Peter Dall; A Hekele; H Ikenberg; A Göppinger; Thomas Bauknecht; A Pfleiderer; Jurgen Moll; Martin Hofmann-Apitius; Helmut Ponta; Peter Herrlich
Increasing incidence of CD44v7/8 epitope expression during uterine cervical carcinogenesis.
International journal of cancer. Journal international du cancer 1996;69(2):79-85.
1996: I Preuss; S Haas; Uta Eichhorn; I Eberhagen; Manfred Kaufmann; T Beck; Robert Eibl; Peter Dall; Thomas Bauknecht; Jan G Hengstler; B M Wittig; W Dippold; Bernd Kaina
Activity of the DNA repair protein O6-methylguanine-DNA methyltransferase in human tumor and corresponding normal tissue.
Cancer detection and prevention 1996;20(2):130-6.
1995: Hans-Gerd Meerpohl; Andreas du Bois; H Kühnle; Hans-Joachim Lück; R Kreienberg; Volker Möbus; Thomas Bauknecht; O Köchli; H Bochtler; K Diergarten
Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.
Seminars in oncology 1995;22(6 Suppl 15):7-12.
1995: D M Spinner; T Brandstetter; M Kiechle-Schwarz; Andreas du Bois; P Angel; Thomas Bauknecht
c-jun expression and growth stimulation in human ovarian carcinoma cell lines following exposure to cytokines.
International journal of cancer. Journal international du cancer 1995;63(3):423-7.
1995: Andreas du Bois; C A Schäfer; W Vach; Heinrich Prömpeler; Thomas Bauknecht; M Breckwoldt
[Effect of pregnancy and labor on serotonin metabolism].
Geburtshilfe und Frauenheilkunde 1995;55(9):500-4.
1995: H Ikenberg; K Matthay; B Schmitt; Thomas Bauknecht; M Kiechle-Schwarz; A Göppinger; A Pfleiderer
p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas.
Cancer 1995;76(1):57-66.
1995: M Kiechle-Schwarz; Thomas Bauknecht; J Schmidt; L Walz; A Pfleiderer
Recurrent cytogenetic aberrations in human ovarian carcinomas.
Cancer detection and prevention 1995;19(3):234-43.
1994: M Kiechle-Schwarz; Thomas Bauknecht; U Karck; Friedrich Kommoss; Andreas du Bois; A Pfleiderer
Recurrent cytogenetic aberrations and loss of constitutional heterozygosity in ovarian carcinomas.
Gynecologic oncology 1994;55(2):198-205.
1994: Friedrich Kommoss; J Wölfle; Thomas Bauknecht; Jacobus Pfisterer; M Kiechle-Schwarz; A Pfleiderer; Willi Sauerbrei; R Kiehl; Barry M Kacinski
Co-expression of M-CSF transcripts and protein, FMS (M-CSF receptor) transcripts and protein, and steroid receptor content in adenocarcinomas of the ovary.
The Journal of pathology 1994;174(2):111-9.
1994: Helmut Madjar; Heinrich Prömpeler; R Wolfahrt; Thomas Bauknecht; A Pfleiderer
[Color Doppler flow data of breast tumors].
Ultraschall in der Medizin (Stuttgart, Germany : 1980) 1994;15(2):69-73.
1994: Andreas du Bois; Hans-Gerd Meerpohl; Helmut Madjar; D Spinner; Peter Dall; Jacobus Pfisterer; Thomas Bauknecht
Phase II study of pirarubicin combined with cisplatin in recurrent ovarian cancer.
Journal of cancer research and clinical oncology 1994;120(3):173-8.
1994: Thomas Bauknecht; M Kiechle-Schwarz; Andreas du Bois; J Wölfle; Barry M Kacinski
Expression of transcripts for CSF-1 and for the "macrophage" and "epithelial" isoforms of the CSF-1R transcripts in human ovarian carcinomas.
Cancer detection and prevention 1994;18(3):231-9.
1993: M Kiechle-Schwarz; Thomas Bauknecht; T Wienker; L Walz; A Pfleiderer
Loss of constitutional heterozygosity on chromosome 11p in human ovarian cancer. Positive correlation with grade of differentiation.
Cancer 1993;72(8):2423-32.
1993: Thomas Bauknecht; P Angel; M Kohler; Friedrich Kommoss; G Birmelin; A Pfleiderer; E Wagner
Gene structure and expression analysis of the epidermal growth factor receptor, transforming growth factor-alpha, myc, jun, and metallothionein in human ovarian carcinomas. Classification of malignant phenotypes.
Cancer 1993;71(2):419-29.
1992: M Kiechle-Schwarz; Friedrich Kommoss; J Schmidt; L Lukovic; L Walz; Thomas Bauknecht; A Pfleiderer
Cytogenetic analysis of an adenoid cystic carcinoma of the Bartholin's gland. A rare, semimalignant tumor of the female genitourinary tract.
Cancer genetics and cytogenetics 1992;61(1):26-30.
1992: M Kohler; Thomas Bauknecht; M Grimm; G Birmelin; Friedrich Kommoss; E Wagner
Epidermal growth factor receptor and transforming growth factor alpha expression in human ovarian carcinomas.
European journal of cancer (Oxford, England : 1990) 1992;28A(8-9):1432-7.
1992: Friedrich Kommoss; Thomas Bauknecht; G Birmelin; M Kohler; H Tesch; A Pfleiderer
Oncogene and growth factor expression in ovarian cancer.
Acta obstetricia et gynecologica Scandinavica. Supplement 1992;155():19-24.
1991: Thomas Bauknecht; Friedrich Kommoss; G Birmelin; S von Kleist; M Kohler; A Pfleiderer
Expression analysis of EGF-R and TGFa in human ovarian carcinomas.
Anticancer research 1991;11(4):1523-8.
1990: Thomas Bauknecht; G Birmelin; Friedrich Kommoss
Clinical significance of oncogenes and growth factors in ovarian carcinomas.
The Journal of steroid biochemistry and molecular biology 1990;37(6):855-62.
1990: Friedrich Kommoss; H O Wintzer; S von Kleist; M Kohler; R Walker; B Langton; K Van Tran; A Pfleiderer; Thomas Bauknecht
In situ distribution of transforming growth factor alpha in normal human tissues and in malignant tumours of the ovary.
The Journal of pathology 1990;162(3):223-30.
1989: M Kohler; I Janz; H O Wintzer; E Wagner; Thomas Bauknecht
The expression of EGF receptors, EGF-like factors and c-myc in ovarian and cervical carcinomas and their potential clinical significance.
Anticancer research 1989;9(6):1537-47.
1989: Thomas Bauknecht; I Janz; M Kohler; A Pfleiderer
Human ovarian carcinomas: correlation of malignancy and survival with the expression of epidermal growth factor receptors (EGF-R) and EGF-like factors (EGF-F).
Medical oncology and tumor pharmacotherapy 1989;6(2):121-7.
1989: Thomas Bauknecht; M Kohler; I Janz; A Pfleiderer
The occurrence of epidermal growth factor receptors and the characterization of EGF-like factors in human ovarian, endometrial, cervical and breast cancer. EGF receptors and factors in gynecological carcinomas.
Journal of cancer research and clinical oncology 1989;115(2):193-9.
1989: A Göppinger; F M Wittmaack; H O Wintzer; H Ikenberg; Thomas Bauknecht
Localization of human epidermal growth factor receptor in cervical intraepithelial neoplasias.
Journal of cancer research and clinical oncology 1989;115(3):259-63.
1988: Thomas Bauknecht; M Runge; M Schwall; A Pfleiderer
Occurrence of epidermal growth factor receptors in human adnexal tumors and their prognostic value in advanced ovarian carcinomas.
Gynecologic oncology 1988;29(2):147-57.